Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in Schizophrenia - Report - MDSpire

Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in Schizophrenia

  • By

  • Florian J. Raabe

  • David Popovic

  • Clara Vetter

  • Laura E. Fischer

  • Genc Hasanaj

  • Berkhan Karslı

  • Tim J. Schäfer

  • Valeria Almeida

  • Alessia Atella

  • Miriam Gagliardi

  • Emanuel Boudriot

  • Vladislav Yakimov

  • Lucia Trastulla

  • Tengjia Jiang

  • Clara Weyer

  • Lukas Roell

  • Joanna Moussiopoulou

  • Lenka Krčmář

  • Sabrina Galinski

  • Irina Papazova

  • Oliver Pogarell

  • Alkomiet Hasan

  • Eva C. Schulte

  • Andrea Schmitt

  • Nikolaos Koutsouleris

  • Anna Levina

  • Elias Wagner

  • Moritz J. Rossner

  • Sergi Papiol

  • Peter Falkai

  • Daniel Keeser

  • Michael J. Ziller

  • CDP Working Group

  • Stephanie Behrens

  • Man-Hsin Chang

  • Valéria de Almeida

  • Sylvia de Jonge

  • Fanny Dengl

  • Lina Dürrwald

  • Nadja Gabellini

  • Vanessa Gabriel

  • Thomas Geyer

  • Katharina Hanken

  • Alexandra Hisch

  • Georgios Ioannou

  • Marcus Ising

  • Iris Jäger

  • Marcel Kallweit

  • Temmuz Karali

  • Susanne Karch

  • Christoph Kern

  • Nicole L. Klimas

  • Maxim Korman

  • Lenka Krcmar

  • Verena Meisinger

  • Julian Melcher

  • Matin Mortazavi

  • Karin Neumeier

  • Frank Padberg

  • Boris Papazov

  • Pauline Pingen

  • Siegfried G. Priglinger

  • Philipp Sämann

  • Susanne Schmölz

  • Enrico Schulz

  • Benedikt Schworm

  • Sophie Seeburger

  • Sven Wichert

  • Peter Zill

  • May 1, 2026

  • 0 min

Share

Clinical Report: Connecting Scales through Customized Cellular Models in Schizophrenia

Overview

Expand on the specific contributions of iPSCs to understanding cognitive deficits.

Background

Schizophrenia is a complex neuropsychiatric disorder characterized by significant cognitive impairments linked to synaptic dysfunction. Understanding the interplay between genetic factors and neurobiological processes is crucial for developing targeted interventions. The integration of personalized disease models, such as iPSCs, offers a promising avenue for exploring these connections and enhancing treatment strategies.

Data Highlights

CohortSample Size (n)Correlation (r)P Value
C1 (SCZ)580.49< .001
C2 (SCZ)760.31< .001
C1 (HC)73--
C2 (HC)84--

Key Findings

  • Identified genetic influences on synaptic density in iPSC-derived neurons from SCZ patients.
  • Established a correlation between cognitive performance and brain structure in SCZ individuals.
  • Utilized machine learning to predict genetically regulated transcriptomes related to SCZ.
  • Demonstrated the potential of iPSCs to bridge molecular changes with cognitive deficits.
  • Highlighted the importance of multimodal phenotyping in understanding SCZ pathology.

Clinical Implications

The findings underscore the potential of personalized iPSC models in elucidating the neurobiological mechanisms underlying cognitive deficits in schizophrenia. Clinicians may consider integrating genetic and phenotypic assessments to tailor interventions more effectively for individuals with SCZ.

Conclusion

This research provides a framework for connecting genetic, molecular, and cognitive aspects of schizophrenia, paving the way for personalized treatment approaches. Further exploration of these connections may enhance our understanding and management of the disorder.

Related Resources & Content

  1. npj Digital Medicine, 2025 -- Diagnostic digital phenotyping in schizophrenia-spectrum disorders: a systematic review
  2. npj Digital Medicine, 2025 -- A Systems Dynamics Approach to Tailored Psychiatry
  3. BMC Psychiatry, 2025 -- Altered Genes and Pathways in Schizophrenia: Comprehensive Analysis of Brain and Blood Samples
  4. Brain, 2025 -- Exploring the Pathophysiology of Neurodevelopmental Disorders Through Brain Organoid Models
  5. Mental Health Clinical Practice Guidelines - VA/DOD Clinical Practice Guidelines, 2025
  6. FDA, 2025 -- FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia
  7. Mental Health Clinical Practice Guidelines - VA/DOD Clinical Practice Guidelines
  8. FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia | FDA
  9. The Effects of Cognitive Remediation on Negative Symptoms in Schizophrenia-Spectrum Illness: A Meta-analytic Investigation of Efficacy

Original Source(s)

Bridging the Scales via Personalized Cellular Modeling and Deep Phenotyping in Schizophrenia

  • by Florian J. Raabe, David Popovic, Clara Vetter, Laura E. Fischer, Genc Hasanaj, Berkhan Karslı, Tim J. Schäfer, Valeria Almeida, Alessia Atella, Miriam Gagliardi, Emanuel Boudriot, Vladislav Yakimov, Lucia Trastulla, Tengjia Jiang, Clara Weyer, Lukas Roell, Joanna Moussiopoulou, Lenka Krčmář, Sabrina Galinski, Irina Papazova, Oliver Pogarell, Alkomiet Hasan, Eva C. Schulte, Andrea Schmitt, Nikolaos Koutsouleris, Anna Levina, Elias Wagner, Moritz J. Rossner, Sergi Papiol, Peter Falkai, Daniel Keeser, Michael J. Ziller, CDP Working Group, Stephanie Behrens, Man-Hsin Chang, Valéria de Almeida, Sylvia de Jonge, Fanny Dengl, Lina Dürrwald, Nadja Gabellini, Vanessa Gabriel, Thomas Geyer, Katharina Hanken, Alexandra Hisch, Georgios Ioannou, Marcus Ising, Iris Jäger, Marcel Kallweit, Temmuz Karali, Susanne Karch, Christoph Kern, Nicole L. Klimas, Maxim Korman, Lenka Krcmar, Verena Meisinger, Julian Melcher, Matin Mortazavi, Karin Neumeier, Frank Padberg, Boris Papazov, Pauline Pingen, Siegfried G. Priglinger, Philipp Sämann, Susanne Schmölz, Enrico Schulz, Benedikt Schworm, Sophie Seeburger, Sven Wichert, Peter Zill

  • May 1, 2026

Related Content

The Tango of Immune and Neural Cells: Orchestrating Neuroinflammation Mediated Brain Disorders

Plasma microRNA signatures in drug-Naïve Romanian adolescents with First-Episode Psychosis

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.